BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis

Frontiers in Pharmacology

Pharmacology

Franziska Elena Herrmann¹  Lutz Wollin¹  Christian Hesslinger¹  Peter Nickolaus² 

[1] Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany;null;

关键词: PDE4B;    IPF;    lung fibrosis;    phosphodiesterase;    cAMP;    ILDs;   

DOI  :  10.3389/fphar.2022.838449

 received in 2021-12-17, accepted in 2022-02-21,  发布年份 2022

来源: Frontiers

【 摘 要 】

Graphical Abstract

【 授权许可】

Unknown   
Copyright © 2022 Herrmann, Hesslinger, Wollin and Nickolaus.